After 8 weeks of treatment ( mean daily dose of 2.5 + / - 0.85 ) , the 16 subjects on risperidone showed a 32 % reduction in tic severity from baseline , compared to a 7 % reduction for placebo patients ( n = 18 ) ( F [ 2,64 ] = 6.07 ; p = 0.004 ) .
